---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-250223"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T05:50:34.492958+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# KalVista secures up to $179M synthetic royalty financing with DRI for sebetralstat launch

## Summary
- Upfront payment of $100M; potential total up to $179M including $22M optional approval payment and $57M sales milestone.
- Tiered royalties: 5% on net sales up to $500M, 1.1% on $500M-$750M, 0.25% above $750M; rate increases if optional payment taken.
- Additional $22M optional if US approval by Sep 30, 2025; PDUFA date June 17, 2025 for sebetralstat (oral HAE therapy).
- DRI expressed non-binding interest in up to $5M private placement of KalVista common stock.
- Royalty financing non-dilutive; proceeds to fund commercial launch of sebetralstat.

## SEC filing metadata
- accession: 0001193125-24-250223
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312524250223/0001193125-24-250223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312524250223/d904891d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-250223
- JSON: https://secwatch.observer/filing/0001193125-24-250223.json
- Plain text: https://secwatch.observer/filing/0001193125-24-250223.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.